Case reports of neuroleptic malignant syndrome in context of quetiapine use

Psychiatric Quarterly

Volumn 84, Issue 4, 2013, Pages 523-541

  Detweiler, Mark B ^a,b   Sullivan, Kelly ^b,c   Sharma, Taral R ^b   Kim, Kye Y ^b   Detweiler, Jonna G ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^c Norfolk Community Services Board   (United States)

Author keywords

Extrapyramidal side effects; Neuroleptic malignant syndrome; Quetiapine; Serotonin syndrome

Indexed keywords

QUETIAPINE;

ADDONIZIO CRITERIA; ADITYANJEE CRITERIA; ADULT; ARTICLE; CAROFF CRITERIA; CLINICAL ARTICLE; DRUG INTOXICATION; DRUG USE; DSM-IV-TR; FRIEDMAN CRITERIA; HUMAN; LEVENSON CRITERIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME CRITERIA; POLYPHARMACY; POPE CRITERIA; PRACTICE GUIDELINE; RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEVER; GUIDELINE ADHERENCE; HUMANS; MENTAL DISORDERS; MIDDLE AGED; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84888644990     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-013-9264-4     Document Type: Article

References (131)

1. Delay J, Pichot P, Lemperiere T, et al.: A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychosis. Annales Medico Psychologiques (Paris) 118:145-152, 1960
2. Caroff SN: The neuroleptic malignant syndrome. Journal of Clinical Psychiatry 41:79-83, 1980.
3. Caroff SN, Mann SC: Neuroleptic malignant syndrome. Psychopharmacology Bulletin 24:25-29, 1988
4. Yamawaki S, Yano E, Terakawa N, et al. Results of second questionnaire about neuroleptic malignant syndrome in Japan (English abstract). Hiroshima Journal of Anesthesia 24:62, 1988
5. Kohen D, Bristow MF: Atypical antipsychotics and neuroleptic malignant syndrome. British Journal of Psychiatry 175:392-393, 1999.
6. Khan M, Farver D: Recognition, assessment and management of neuroleptic malignant syndrome. South Dakota Journal of Medicine 53:395-400, 2000
7. Stubner S, Rustenbeck E, Grohmann R, et al.: Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37(suppl 1):S54-S64, 2004
8. Strawn JR, Keck PE Jr, Caroff SN: Neuroleptic malignant syndrome. American Journal of Psychiatry 164(6):870-876, 2007.
9. Caroff SN, Mann SC, Lazarus A, et al.: Neuroleptic malignant syndrome: diagnostic issues. Psychiatric Annales 21:130-147, 1991
10. Caroff SN, Mann SC: Neuroleptic malignant syndrome. Medical Clinics of North America, 77:185-202, 1993
11. Kaufman KR, Levitt MJ, Schiltz JF, et al.: Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: Case analysis. Annals of Clinical Psychiatry 18:201-204, 2006
12. Keyser DL, Rodnitzky RL: Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. The Archives of Internal Medicine 151:794-796, 1991
13. Lu ML, Pan JJ, HW Teng HW, et al.: Metoclopramide-induced super sensitivity psychosis. The Annals of Pharmacotherapy 36:1387-1390, 2002
14. Odagaki Y: Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Current Drug Safety 4:84-93, 2009
15. Kurlan R. Hamill R, Shoulson I: Neuroleptic malignant syndrome. Clinical Neuropharmacology 7:109-120, 1984
16. Levenson JL: Neuroleptic malignant syndrome. American Journal of Psychiatry 142:1137-1145, 1985
17. Addonizio G, Susman VI, Roth SD: Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. American Journal of Psychiatry 143:1587-1590, 1986
18. Pope HG, Keck PE, McElroy SL: Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry 143:1227-1233, 1986
19. Harsch HH: Neuroleptic malignant syndrome: Physiological and laboratory findings in a series of nine cases. Journal of Clinical Psychiatry 48:328-333, 1987
20. Friedman JH, Davis R, Wagner RL: Neuroleptic malignant syndrome: The results of a 6-month prospective study of incidence in a state psychiatric hospital. Clinical Neuropharmacology 11:373-377, 1988
21. Warner MD, Peabodt CA, Boutros NN: A survey of neuroleptic malignant syndrome. Journal of Nervous and Mental Disease 178:664-665, 1990
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. Washington, DC, American Psychiatric Association, 2000
23. Adityanjee, Singh S, Singh G, Ong S: Spectrum concept of neuroleptic malignant syndrome. British Journal of Psychiatry 153:107-111, 1988
24. Adityanjee, Mathews T, Aderibigbe YA: Proposed research diagnostic criteria for neuroleptic malignant syndrome. International Journal of Neuropsychopharmacology 2:129-144,1999
25. Gurrera RJ, Caroff SN, Cohen A, et al: An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. Journal of Clinical Psychiatry 72:1222-12228, 2011
26. Hasan S, Buckley P: Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. American Journal of Psychiatry 155:1113-1116, 1998
27. Caroff SN, Mann SC, Campbell EC: Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals 30:314-321, 2000
28. Ananth J, Parameswaran S, Gunatilake S, et al.: Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry 65:464-470, 2004
29. McEwan B: Allostasis and allostatic load. Implication for neuropsychopharmacology. Neuropsychopharmacology 22:108-124, 2000
30. Bhana N, Foster RH, Olney R, et al.: Olanzapine: An updated review of its use in the management of schizophrenia. Drugs 61:111-161, 2001
31. Farver DK: Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opinion on Drug Safety 2:21-35, 2003
32. Reeves RR, Torres RA, Liberto V, et al.: Atypical neuroleptic syndrome associated with olanzapine. Pharmacotherapy 22:641-644, 2002
33. Alexopoulos GS, Streim JE, Carpenter D, et al.: Using antipsychotic agents in older patients. Journal of Clinical Psychiatry 65(suppl 2):5-104, 2004
34. Addonizio G, Susman VL, Roth SD: Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biological Psychiatry 22:1004-1020, 1987
35. Sing KJ, Ramaekers GM, Van Harten PN: Neuroleptic malignant syndrome and quetiapine. American Journal of Psychiatry 159:149-150, 2002
36. Whalley N, Diaz P, Howard J. Neuroleptic malignant syndrome associated with the use of quetiapine (letter). Canadian Journal of Hospital Pharmacy 52:112, 1999
37. Matsumoto R, Kitabayashi Y, Nakatomi Y, et al: Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. American Journal of Psychiatry 162:812, 2005
38. Dan A, Bharadwaj R, Grover S: Neuroleptic malignant syndrome with use of quetiapine in mental retardation. Psychiatry and Clinical Neurosciences 63:255-256, 2009
39. Kobayashi A, Kawanishi C, Matsumura T, et al.: Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: A case report. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30:1170-1172, 2006
40. Lai TS, Lam SM: Quetiapine induced neuroleptic malignant syndrome. The Hong Kong medical diary. Medical Bulletin 14:16-18, 2009
41. Khan KH, Tham TC: Neuroleptic malignant syndrome induced by quetiapine overdose. British Journal of Hospital Medicine 69:171, 2008
42. Stanley AK, Hunter J: Possible neuroleptic malignant syndrome with quetiapine. British Journal of Psychiatry 176:497, 2000
43. Solomons K: Quetiapine and neuroleptic malignant syndrome. Canadian Journal of Psychiatry 47:791, 2002
44. Bourgeois JA, Babine S, Meyerovish M, et al.: A case of neuroleptic malignant syndrome with quetiapine. Journal of Neuropsychiatry & Clinical Neurosciences 14:87, 2002
45. Gortney JS, Fagan A, Kissack J: Neuroleptic malignant syndrome secondary to quetiapine. Annals of Pharmacotherapy 43:785-791, 2009
46. Sugden SG, Bourgeois JA, Kile SJ, et al.: Neuroleptic malignant syndrome with dermatologic complications. Journal of Clinical Psychopharmacology 24:676-678, 2004
47. Suzuki K, Awata S, Nakagawa K, et al.: Catatonic stupor during the course of Parkinson's disease resolved with electroconvulsive therapy. Movement Disorders 21:123-130, 2006
48. Chungh DS, Kim BN, Cho SC: Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. Journal of Psychopharmacology 19:422-425, 2005
49. Grignon S, Brethes JI, Chamberland M, et al.: Incipient neuroleptic malignant syndrome with quetiapine/paroxetine combination treatment: Atypical presentation and early, successful rechallenge with olanzapine. International Journal of Psychiatry in Clinical Practice 9:296-298, 2005
50. Seitz DP: Diagnostic uncertainty in a case of neuroleptic malignant syndrome. Canadian Journal of Emergency Medicine 7:266-272, 2005
51. Nierenberg D, Disch M, Manheimer E, et al.: Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome. Clinical Pharmacology & Therapeutics 50:580-586, 1991
52. Sachdev P, Kruk J, Kneebone M, et al.: Clozapine-induced neuroleptic malignant syndrome: Review and report of new cases. Journal of Clinical Psychopharmacology 15:365-371, 1995
53. Sachdev P, Mason C, Hadzi-Pavlovic D: Case-control study of neuroleptic malignant syndrome. American Journal of Psychiatry 154:1156-1158, 1997
54. Lev R, Clark RF. Neuroleptic malignant syndrome presenting without fever: Case report and review of the literature. Journal of Emergency Medicine 12:49-55, 1994
55. Fink M, Taylor MA: The many varieties of catatonia. European Archives of Psychiatry and Clinical Neuroscience 251(suppl 1):8-13, 2001
56. Précourt A, Dunewicz M, Grégoire G, et al.: Multiple complications and withdrawal syndrome associated with quetiapine/venlafaxine intoxication. Annals of Pharmacotherapy 39:153-156, 2005
57. Lazarus A, Mann SC, Caroff SN. The Neuroleptic Malignant Syndrome and Related Conditions. Washington, DC, American Psychiatric Press, 1998
58. Keck PE Jr, Pope HG Jr, Cohen BM, et al.: Risk factors for neuroleptic malignant syndrome. Archives General Psychiatry 46:914-918, 1989
59. Nicklason FN, Finucane PM, Pathy MJ, et al.: Neuroleptic malignant syndrome: An unrecognized problem in elderly patients with psychiatric illness? International Journal of Geriatric Psychiatry 6:171-175, 1991
60. Webster P, Wijeratne C: Risperidone-induced neuroleptic malignant syndrome. Lancet 344:1228-1229, 1994
61. Mills KC. Serotonin syndrome. A clinical update. Critical Care Clinics 13:763-783, 1997
62. Adityanjee, Jayaswal SK, Chant SP, et al.: Case report: Neuroleptic malignant syndrome in an elderly patient: Problems in management. International Journal of Geriatric Psychiatry 7:843-846, 1992
63. Becker T, Kornhuber J, Hofmann E, et al.: MRI white matter hyperintensity in neuroleptic malignant syndrome (NMS) - A clue to pathogenesis? Journal of Neural Transmission 90:151-159, 1992
64. S Cooper S, Greene JDW: The clinical assessment of the patient with early dementia. Journal of Neurology, Neurosurgery, and Psychiatry 76:15-24, 2005
65. Wong DF, Wagner HN, Dannals RF, et al.: Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226:1393-1396, 1984
66. Serby M: Neuroleptic malignant syndrome in Alzheimer's disease. Journal of the American Geriatrics Society 34:895-896, 1986
67. Bora E, Gonul S, Akdeniz F, Vahip S. Neuroleptic malignant-like syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. European Psychiatry 18:323, 2003
68. Deng MZ, Chen GQ, Phillips MR: Neuroleptic malignant syndrome in 12 of 9,792 Chinese patients exposed to neuroleptics: A prospective study. American Journal of Psychiatry 147:1149-1155, 1990
69. Aydin N, Anac E, Caykoylu A, Akcay F: Neuroleptic malignant syndrome due to citalopram overdose. Canadian Journal of Psychiatry 45:941-942, 2000
70. Hamburg P, Weilburg JB, Cassem NH, et al.: Relapse of neuroleptic malignant syndrome with early discontinuation of amantadine therapy. Comprehensive Psychiatry 27:272-275, 1986
71. Ito T, Shibata K, Watanabe A, Akabane J: Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza A encephalopathy. European Journal of Pediatrics 160:401, 2001
72. Newman EJ, Kieran Breen K, Patterson J, et al.: Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Movement Disorders 24:2379-2385, 2009
73. Bilbao Garay J, Mesa Plaza N, Castilla Castellano V, et al.: Serotonin syndrome: Report of a fatal case and review of the literature. Revista Clínica Española 202:209-211, 2002 (Article in Spanish)
74. Hinds NP, Hillier CE, Wiles CM: Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. Journal of Neurology 247:811, 2000
75. FDA ALERT [7/2006]: Potentially Life-Threatening Serotonin Syndrome with Combined Use of SSRIs or SNRIs and Triptan Medications http://www.fda.gov/drugs/ drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm125925.htm. Accessed March 12, 2012
76. McCue RE Joseph M: Venlafaxine- and trazodone-induced serotonin syndrome. American Journal of Psychiatry 158:2088-2089, 2001
77. Bhatara VS, Magnus RD, Paul KL, et al: serotonin syndrome induced by venlafaxine and fluoxetine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Annals of Pharmacotherapy 32:432-436, 1998
78. Leela JL, Perreault MM, Tao T, et al.: Serotonin syndrome associated with nefazodone and paroxetine. Annals of Emergency Medicine 29:287-289, 1997
79. Velez LI, Shepherd G, Roth BA, et al.: Serotonin syndrome with elevated paroxetine concentrations. Annals of Pharmacotherapy 38:269-272, 2004
80. El-Gaaly S, St John P, Dunsmore S, et al.: Atypical neuroleptic malignant syndrome with quetiapine: A case report and review of literature. Journal of Clinical Psychopharmacology 29:497-499, 2009
81. Mahlberg R, Kunz D, Sasse J, Kircheiner J: Serotonin syndrome with tramadol and citalopram. American Journal of Psychiatry 161:1129, 2004
82. Cheng BHW, Mok WWY. Serotonin syndrome after taking citalopram. Asian Journal of Gerontology and Geriatrics 4:76-78, 2009
83. Marlowe K, Schirgel D: Quetiapine and citalopram: Aetiological significance in serotonin syndrome. New Zealand Medical Journal 119:59-62, 2006
84. Ebert D, Albert R, May A, et al.: The serotonin syndrome and psychosis-like side-effects of fluvoxamine in clinical use - An estimation of incidence. European Neuropsychopharmacology 7:71-74, 1997
85. Demers JC, Malone M: Serotonin syndrome induced by fluvoxamine and mirtazapine. Annals of Pharmacotherapy 35:1217-1220, 2001
86. Kaneda Y, Ishimoto Y, Ohmori T: Mild serotonin syndrome on fluvoxamine. International Journal of Neuroscience 109:165-172, 2001
87. Ehara H, Maegaki Y, Takeshita K: Neuroleptic malignant syndrome and methylphenidate. Pediatric Neurology 19:299-301, 1998
88. Basil B, Mathews M, Budur K: Methylphenidate-induced neuroleptic malignant syndrome: A case report. Primary Care Companion To the Journal of Clinical Psychiatr 8:47, 2006
89. Ishii M, Tatsuzawa Y, Yoshino A, et al.: Serotonin syndrome induced by augmentation of SSRI with methylphenidate. Psychiatry and Clinical Neurosciences 62:246, 2008
90. Susman VL, Addonizio G: Reinduction of neuroleptic malignant syndrome by lithium. Journal of Clinical Psychopharmacology 7:339-341, 1987
91. Brown CH: Drug-induced serotonin syndrome. US Pharm 35(11):HS-16-HS-21, 2010
92. Carter CJ, Pycock CJ: Possible importance of hydroxytryptamine in neuroleptic-induced catalepsy in rats [proceedings]. British Journal of Pharmacology 60:267P-268P, 1977
93. Baldessarini RJ, March E: Fluoxetine and side effects. Archives of General Psychiatry 47:191-192, 1990
94. Rosebush PI, Stewart TD, Gelenberg AJ: Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. Journal of Clinical Psychiatry 50:295-298, 1989
95. Nisijima K, Ishiguro T: Neuroleptic malignant syndrome: A study of CSF monoamine metabolism. Biological Psychiatry 27:280-288, 1991
96. Viejo LF, Morales V, Puñal P, et al.: Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatrica Scandinavica 107:45-49, 2003
97. Boyd RD. Neuroleptic malignant syndrome and mental retardation: Review and analysis of 29 cases. American Journal of Mental Retardation 98:143-155, 1993
98. Margolese HC, Chouinard G: Olanzapine-induced neuroleptic malignant syndrome. American Journal of Psychiatry 156:1115a-6, 1999
99. Tanii T, Ichihashi K, Inoue K, et al.: Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30:1176-1178, 2006a
100. Pearlman CA: Neuroleptic malignant syndrome: A review of the literature. Journal of Clinical Psychopharmacology 6:257-273, 1986
101. Chong LS, Abbott PM: Neuroleptic malignant syndrome secondary to loxapine. British Journal of Psychiatry 159:572-573, 1991
102. Geethan J, Chandran GJ, Mikler JR, et al.: Neuroleptic malignant syndrome: Case report and discussion. CMAJ 169:439-442, 2003
103. Kashihara K, Ishida K: Neuroleptic malignant syndrome due to sulpiride. Journal of Neurology, Neurosurgery, and Psychiatry 51:1109-1110, 1988
104. Peet M, Collier J: A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. Journal of Psychopharmacology 25:755-762, 2011
105. Matthews SJ, Cersosimo RJ: Haloperidol induced neuroleptic malignant syndrome. Clinical Research and Regulatory Affairs 4:33-41, 1986
106. Wilkinson R, Meythaler JM, Guin-Renfore S: Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Injury 13:1025-1031, 1999
107. Mahmood T, Warren JP: Neuroleptic malignant syndrome from chlorpromazine: Case report. Journal of Royal College of General Practitioners 39:211, 1989
108. RxMed: Pharmaceutical Information: Chlorpromazine General Monograph http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-Monographs/ CPS-(GeneralMonographs-C)/CHLORPROMAZINE.html. Accessed 2.22.2012.
109. Khaldarov V: Benzodiazepines for treatment of neuroleptic malignant syndrome. Hospital Physician 6:51-55, 2000
110. Mahendran R, Winslow M, Lim D: Recurrent neuroleptic malignant syndrome. Australian and New Zealand Journal of Psychiatry 34:699-700, 2000
111. Arnaout MS, Antun FP, Ashkar K: Neuroleptic malignant syndrome with olanzapine associated with severe hypernatremia. Human Psychopharmacology Clinical and Experimental 16:279-281, 2001
112. Nielsen J, Bruhn AM: Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatrica Scandinavica 112:238-240, 2005
113. Norgard NB, Jennifer E Stark JE: Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 26:1180-1182, 2006
114. Tsai G, Crisostomo G, Rosenblatt ML, et al.: Neuroleptic malignant syndrome associated with clozapine treatment. Annals of Clinical Psychiatry 7:91-95, 1995
115. Karagianis JL, Phillips LC, Hogan KP, et al.: Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature. Annals of Pharmacotherapy 33:623-630, 1999
116. Newman M, Adityanjee, Jampala C: Atypical neuroleptic malignant syndrome associated with risperidone treatment (letter). American Journal of Psychiatry 154:1475, 1997
117. Sharma R, Trappler B, Ng YK, et al.: Risperidone-induced neuroleptic malignant syndrome. Annals of Pharmacotherapy 30:775-778, 1996
118. Edgar J: Droperidol-induced neuroleptic malignant syndrome. Hospital Medicine 60:448-450, 1999
119. So PC: Neuroleptic malignant syndrome induced by droperidol. Hong Kong Medical Journal 7:101-103, 2001
120. Wells AJ, Sommi RW, Crismon ML: Neuroleptic rechallenge after neuroleptic malignant syndrome: Case report and literature review. Drug Intelligence & Clinical Pharmacy 22:475-480, 1988
121. Hatch CD, Lund BC, Perry PJ: Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotic. Pharmacotherapy 21:1003-1006, 2001
122. Cookson JC, Katona CLE, Taylor D: Use of Drugs in Psychiatry; the Evidence from Psychopharmacology, 5th edn. London, Gaskell, 2002
123. Chang K, Adleman NE, Dienes K, et al.: Anomalous prefrontal-subcortical activation in familial pediatric bipolar disorder: A functional magnetic resonance imaging investigation. Archives General Psychiatry 61:781-792, 2004
124. Brieger P, Reinelt Y: No recurrence of a neuroleptic malignant syndrome under quetiapine. Australian and New Zealand Journal of Psychiatry 35:627, 2003
125. Thomas P, Maron M, Rascle C, et al.: Carbamazepine in the treatment of neuroleptic malignant syndrome. Biological Psychiatry 43:303-305, 1998
126. Tadke RR, Suryavanshi P: Use of intravenous valproate in a patient with neuroleptic malignant syndrome. Journal of Neuropsychiatry & Clinical Neurosciences 18:131-132, 2006
127. Francis A, Chandragiri S, Rizvi S, et al.: Is lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectrums 5:54-57, 2000
128. Northoff G: Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. Journal of Neural Transmission 109:1453-1467, 2002
129. Miyaoka H, Shishikura K, Otsubo T: Diazepam-responsive neuroleptic malignant syndrome: A diagnostic subtype? American Journal of Psychiatry 154:882, 1997
130. Kasantikul D, Kanchanatawan B: Neuroleptic malignant syndrome: A review and report of six cases. Journal of the Medical Association of Thailand's 89:2155-2160, 2007
131. al-Waneen R: Neuroleptic malignant syndrome associated with quetiapine. Canadian Journal of Psychiatry 45:764-765, 2000